Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 262

1.

Influence of retronectin-mediated T cell activation on expansion and phenotype of CD19-specific chimeric antigen receptor T cells.

Stock S, Hoffmann JM, Schubert ML, Wang L, Wang S, Gong W, Neuber B, Gern U, Schmitt A, Müller-Tidow C, Dreger P, Schmitt M, Sellner L.

Hum Gene Ther. 2018 Jul 19. doi: 10.1089/hum.2017.237. [Epub ahead of print]

PMID:
30024314
2.

Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth.

Bäumer N, Rehkämper J, Appel N, Terheyden L, Hartmann W, Wardelmann E, Buchholz F, Müller-Tidow C, Berdel WE, Bäumer S.

PLoS One. 2018 Jul 12;13(7):e0200163. doi: 10.1371/journal.pone.0200163. eCollection 2018.

3.

CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.

Pulikkan JA, Hegde M, Ahmad HM, Belaghzal H, Illendula A, Yu J, O'Hagan K, Ou J, Muller-Tidow C, Wolfe SA, Zhu LJ, Dekker J, Bushweller JH, Castilla LH.

Cell. 2018 Jun 28;174(1):172-186.e21. doi: 10.1016/j.cell.2018.05.048.

PMID:
29958106
4.

appreci8: A Pipeline for Precise Variant Calling Integrating 8 Tools.

Sandmann S, Karimi M, de Graaf AO, Rohde C, Göllner S, Varghese J, Ernsting J, Walldin G, van der Reijden BA, Müller-Tidow C, Malcovati L, Hellström-Lindberg E, Jansen JH, Dugas M.

Bioinformatics. 2018 Jun 26. doi: 10.1093/bioinformatics/bty518. [Epub ahead of print]

PMID:
29945233
5.

BCR-ABL+ acute myeloid leukemia: are we always dealing with a high-risk disease?

Neuendorff NR, Hemmati P, Arnold R, Ihlow J, Dörken B, Müller-Tidow C, Westermann J.

Blood Adv. 2018 Jun 26;2(12):1409-1411. doi: 10.1182/bloodadvances.2018015594. No abstract available.

6.

Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.

Ottmann OG, Müller-Tidow C, Krämer A, Schlenk RF, Lübbert M, Bug G, Krug U, Bochtler T, Voss F, Taube T, Liu D, Garin-Chesa P, Döhner H.

Br J Haematol. 2018 Jun 8. doi: 10.1111/bjh.15204. [Epub ahead of print] No abstract available.

PMID:
29882583
7.

Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer.

Mikesch JH, Schwammbach D, Hartmann W, Schmidt LH, Schliemann C, Angenendt L, Wiewrodt R, Marra A, Thoennissen NH, Wardelmann E, Köhler G, Lenz G, Müller-Tidow C, Berdel WE, Arteaga MF.

Eur Respir J. 2018 Jul 11;52(1). pii: 1701637. doi: 10.1183/13993003.01637-2017. Print 2018 Jul.

PMID:
29853494
8.

CD7 is expressed on a subset of normal CD34-positive myeloid precursors.

Kriegsmann K, Löffler H, Eckstein V, Schulz R, Kräker S, Braun U, Luft T, Hegenbart U, Schönland S, Dreger P, Krämer A, Ho AD, Müller-Tidow C, Hundemer M.

Eur J Haematol. 2018 May 24. doi: 10.1111/ejh.13100. [Epub ahead of print]

PMID:
29797671
9.

RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.

Rudat S, Pfaus A, Cheng YY, Holtmann J, Ellegast JM, Bühler C, Marcantonio DD, Martinez E, Göllner S, Wickenhauser C, Müller-Tidow C, Lutz C, Bullinger L, Milsom MD, Sykes SM, Fröhling S, Scholl C.

Leukemia. 2018 Mar 22. doi: 10.1038/s41375-018-0102-4. [Epub ahead of print]

PMID:
29654265
10.

Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.

Kriegsmann K, Dittrich T, Neuber B, Awwad MHS, Hegenbart U, Goldschmidt H, Hillengass J, Hose D, Seckinger A, Müller-Tidow C, Ho AD, Schönland S, Hundemer M.

Cytometry B Clin Cytom. 2018 Mar 25. doi: 10.1002/cyto.b.21636. [Epub ahead of print]

PMID:
29577600
11.

miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia.

Krakowsky RHE, Wurm AA, Gerloff D, Katzerke C, Bräuer-Hartmann D, Hartmann JU, Wilke F, Thiede C, Müller-Tidow C, Niederwieser D, Behre G.

Blood Cancer J. 2018 Mar 21;8(3):36. doi: 10.1038/s41408-018-0070-y. No abstract available.

12.

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, Rème T, Robert N, Requirand G, Boireau S, Müller-Tidow C, Veyrune JL, Vincent L, Bouhya S, Goldschmidt H, Vanderkerken K, Hose D, Klein B, De Bruyne E, Moreaux J.

Br J Cancer. 2018 Apr;118(8):1062-1073. doi: 10.1038/s41416-018-0025-x. Epub 2018 Mar 2.

PMID:
29500406
13.

Deficiency of the BMP Type I receptor ALK3 partly protects mice from anemia of inflammation.

Gallitz I, Lofruthe N, Traeger L, Bäumer N, Hoerr V, Faber C, Kuhlmann T, Müller-Tidow C, Steinbicker AU.

BMC Physiol. 2018 Feb 27;18(1):3. doi: 10.1186/s12899-018-0037-z.

14.

Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients.

Hoffmann JM, Schubert ML, Wang L, Hückelhoven A, Sellner L, Stock S, Schmitt A, Kleist C, Gern U, Loskog A, Wuchter P, Hofmann S, Ho AD, Müller-Tidow C, Dreger P, Schmitt M.

Front Immunol. 2018 Jan 10;8:1956. doi: 10.3389/fimmu.2017.01956. eCollection 2017.

15.

Single Nucleotide Polymorphisms in CD40L Predict Endothelial Complications and Mortality After Allogeneic Stem-Cell Transplantation.

Rachakonda SP, Dai H, Penack O, Blau O, Blau IW, Radujkovic A, Müller-Tidow C, Kumar R, Dreger P, Luft T.

J Clin Oncol. 2018 Mar 10;36(8):789-800. doi: 10.1200/JCO.2017.76.4662. Epub 2018 Jan 25.

PMID:
29369699
16.

Obesity is a significant susceptibility factor for idiopathic AA amyloidosis.

Blank N, Hegenbart U, Dietrich S, Brune M, Beimler J, Röcken C, Müller-Tidow C, Lorenz HM, Schönland SO.

Amyloid. 2018 Mar;25(1):37-45. doi: 10.1080/13506129.2018.1429391. Epub 2018 Jan 24.

PMID:
29364741
17.

Bone marrow laminins influence hematopoietic stem and progenitor cell cycling and homing to the bone marrow.

Susek KH, Korpos E, Huppert J, Wu C, Savelyeva I, Rosenbauer F, Müller-Tidow C, Koschmieder S, Sorokin L.

Matrix Biol. 2018 Apr;67:47-62. doi: 10.1016/j.matbio.2018.01.007. Epub 2018 Jan 31.

PMID:
29360499
18.

Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection.

Kriegsmann K, Schmitt A, Kriegsmann M, Bruckner T, Anyanwu A, Witzens-Harig M, Müller-Tidow C, Klein S, Wuchter P.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1281-1288. doi: 10.1016/j.bbmt.2018.01.007. Epub 2018 Jan 17.

PMID:
29353110
19.

A new option for remission induction in acute myeloid leukaemia.

Müller-Tidow C, Schlenk RF.

Lancet Oncol. 2018 Feb;19(2):156-157. doi: 10.1016/S1470-2045(18)30012-3. Epub 2018 Jan 12. No abstract available.

PMID:
29339096
20.

Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction.

Pohlen M, Thoennissen NH, Braess J, Thudium J, Schmid C, Kochanek M, Kreuzer KA, Lebiedz P, Görlich D, Gerth HU, Rohde C, Kessler T, Müller-Tidow C, Stelljes M, Hullerman C, Büchner T, Schlimok G, Hallek M, Waltenberger J, Hiddemann W, Berdel WE, Heilmeier B, Krug U.

PLoS One. 2018 Jan 2;13(1):e0190802. doi: 10.1371/journal.pone.0190802. eCollection 2018.

21.

ABR, a novel inducer of transcription factor C/EBPα, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia.

Namasu CY, Katzerke C, Bräuer-Hartmann D, Wurm AA, Gerloff D, Hartmann JU, Schwind S, Müller-Tidow C, Hilger N, Fricke S, Christopeit M, Niederwieser D, Behre G.

Oncotarget. 2017 Oct 26;8(61):103626-103639. doi: 10.18632/oncotarget.22093. eCollection 2017 Nov 28.

22.

Chimeric antigen receptor transduced T cells: Tuning up for the next generation.

Schubert ML, Hoffmann JM, Dreger P, Müller-Tidow C, Schmitt M.

Int J Cancer. 2018 May 1;142(9):1738-1747. doi: 10.1002/ijc.31147. Epub 2017 Nov 27. Review.

PMID:
29119551
23.

Hematopoietic transcription factors and differential cofactor binding regulate PRKACB isoform expression.

Kuvardina ON, Herkt S, Meyer A, Schneider L, Yillah J, Kohrs N, Bonig H, Seifried E, Müller-Tidow C, Lausen J.

Oncotarget. 2017 Apr 24;8(42):71685-71698. doi: 10.18632/oncotarget.17386. eCollection 2017 Sep 22.

24.

Correction: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.

Sun H, Lin DC, Guo X, Masouleh BK, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, Koeffler HP.

Oncotarget. 2017 Sep 8;8(38):64651. doi: 10.18632/oncotarget.20707. eCollection 2017 Sep 8.

25.

Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients.

Kayser S, Feszler M, Krzykalla J, Schick M, Kramer M, Benner A, Thol F, Platzbecker U, Müller-Tidow C, Ho AD, Ehninger G, Heuser M, Schlenk RF, Thiede C, Röllig C, Krämer A.

Eur J Haematol. 2017 Dec;99(6):544-552. doi: 10.1111/ejh.12972. Epub 2017 Oct 13.

PMID:
28940816
26.

Successful collection of peripheral blood stem cells upon VIDE chemomobilization in sarcoma patients.

Kriegsmann K, Heilig C, Cremer M, Novotny P, Kriegsmann M, Bruckner T, Müller-Tidow C, Egerer G, Wuchter P.

Eur J Haematol. 2017 Nov;99(5):459-464. doi: 10.1111/ejh.12960. Epub 2017 Oct 10.

PMID:
28884875
27.

Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis.

Jordan K, Blättermann L, Hinke A, Müller-Tidow C, Jahn F.

Support Care Cancer. 2018 Jan;26(1):21-32. doi: 10.1007/s00520-017-3857-7. Epub 2017 Aug 31. Review.

PMID:
28861627
28.

Relapsed/refractory acute myeloid leukemia: any progress?

Schlenk RF, Müller-Tidow C, Benner A, Kieser M.

Curr Opin Oncol. 2017 Nov;29(6):467-473. doi: 10.1097/CCO.0000000000000404. Review.

PMID:
28857842
29.

Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancer.

Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Görlich D, Marra A, Hillejan L, Müller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwöppe C, Hartmann W.

PLoS One. 2017 Aug 9;12(8):e0183201. doi: 10.1371/journal.pone.0183201. eCollection 2017.

30.

Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.

Meißner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Müller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M.

Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4). pii: a001677. doi: 10.1101/mcs.a001677. Print 2017 Jul.

31.

An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

Angenendt L, Reuter S, Kentrup D, Benk AS, Neumann F, Hüve J, Martens AC, Schwöppe C, Kessler T, Schmidt LH, Sauer T, Brand C, Mikesch JH, Lenz G, Mesters RM, Müller-Tidow C, Hartmann W, Wardelmann E, Neri D, Berdel WE, Roesli C, Schliemann C.

Leukemia. 2018 Feb;32(2):510-519. doi: 10.1038/leu.2017.208. Epub 2017 Jun 30.

PMID:
28663580
32.

AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia.

Zhou F, Liu Y, Rohde C, Pauli C, Gerloff D, Köhn M, Misiak D, Bäumer N, Cui C, Göllner S, Oellerich T, Serve H, Garcia-Cuellar MP, Slany R, Maciejewski JP, Przychodzen B, Seliger B, Klein HU, Bartenhagen C, Berdel WE, Dugas M, Taketo MM, Farouq D, Schwartz S, Regev A, Hébert J, Sauvageau G, Pabst C, Hüttelmaier S, Müller-Tidow C.

Nat Cell Biol. 2017 Jul;19(7):844-855. doi: 10.1038/ncb3563. Epub 2017 Jun 26.

PMID:
28650479
33.

DDX41-related myeloid neoplasia.

Maciejewski JP, Padgett RA, Brown AL, Müller-Tidow C.

Semin Hematol. 2017 Apr;54(2):94-97. doi: 10.1053/j.seminhematol.2017.04.007. Epub 2017 Apr 21. Review.

PMID:
28637623
34.

Therapy of older persons with acute myeloid leukaemia.

Krug U, Gale RP, Berdel WE, Müller-Tidow C, Stelljes M, Metzeler K, Sauerland MC, Hiddemann W, Büchner T.

Leuk Res. 2017 Sep;60:1-10. doi: 10.1016/j.leukres.2017.05.020. Epub 2017 Jun 1. Review.

PMID:
28618329
35.

Potential therapeutic impact of CD13 expression in non-small cell lung cancer.

Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Görlich D, Marra A, Hillejan L, Müller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwöppe C, Hartmann W.

PLoS One. 2017 Jun 12;12(6):e0177146. doi: 10.1371/journal.pone.0177146. eCollection 2017. Erratum in: PLoS One. 2017 Aug 9;12 (8):e0183201.

36.

Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.

Schaffrath J, Schmoll HJ, Voigt W, Müller LP, Müller-Tidow C, Mueller T.

PLoS One. 2017 Jun 7;12(6):e0178930. doi: 10.1371/journal.pone.0178930. eCollection 2017.

37.

Inhibition of EZH2 degradation as a novel approach to overcome drug resistance in acute myeloid leukemia.

Göllner S, Müller-Tidow C.

Mol Cell Oncol. 2017 Feb 15;4(2):e1291396. doi: 10.1080/23723556.2017.1291396. eCollection 2017.

38.

Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.

Thoennissen GB, Görlich D, Bacher U, Aufenberg T, Hüsken AC, Hansmeier AA, Evers G, Mikesch JH, Fritz F, Bokemeyer C, Müller-Tidow C, Stelljes M, Mesters RM, Krug U, Kropff MH, Thoennissen NH, Berdel WE.

Acta Haematol. 2017;137(3):163-172. doi: 10.1159/000463534. Epub 2017 Apr 12.

39.

Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia.

Mohr S, Doebele C, Comoglio F, Berg T, Beck J, Bohnenberger H, Alexe G, Corso J, Ströbel P, Wachter A, Beissbarth T, Schnütgen F, Cremer A, Haetscher N, Göllner S, Rouhi A, Palmqvist L, Rieger MA, Schroeder T, Bönig H, Müller-Tidow C, Kuchenbauer F, Schütz E, Green AR, Urlaub H, Stegmaier K, Humphries RK, Serve H, Oellerich T.

Cancer Cell. 2017 Apr 10;31(4):549-562.e11. doi: 10.1016/j.ccell.2017.03.001.

40.

Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.

Silva P, Neumann M, Schroeder MP, Vosberg S, Schlee C, Isaakidis K, Ortiz-Tanchez J, Fransecky LR, Hartung T, Türkmen S, Graf A, Krebs S, Blum H, Müller-Tidow C, Thiede C, Ehninger G, Serve H, Hecht J, Berdel WE, Greif PA, Röllig C, Baldus CD.

Leukemia. 2017 Jul;31(7):1640-1644. doi: 10.1038/leu.2017.109. Epub 2017 Apr 3. No abstract available.

PMID:
28366934
41.

The endochondral bone protein CHM1 sustains an undifferentiated, invasive phenotype, promoting lung metastasis in Ewing sarcoma.

von Heyking K, Calzada-Wack J, Göllner S, Neff F, Schmidt O, Hensel T, Schirmer D, Fasan A, Esposito I, Müller-Tidow C, Sorensen PH, Burdach S, Richter GHS.

Mol Oncol. 2017 Sep;11(9):1288-1301. doi: 10.1002/1878-0261.12057. Epub 2017 Aug 21.

42.

Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle Arrest.

Lützkendorf J, Wieduwild E, Nerger K, Lambrecht N, Schmoll HJ, Müller-Tidow C, Müller LP.

PLoS One. 2017 Jan 12;12(1):e0169921. doi: 10.1371/journal.pone.0169921. eCollection 2017.

43.

Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Göllner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S, Stölzel F, Herold S, Ehninger G, Köhler G, Pan KT, Urlaub H, Serve H, Dugas M, Spiekermann K, Vick B, Jeremias I, Berdel WE, Hansen K, Zelent A, Wickenhauser C, Müller LP, Thiede C, Müller-Tidow C.

Nat Med. 2017 Jan;23(1):69-78. doi: 10.1038/nm.4247. Epub 2016 Dec 12.

PMID:
27941792
44.

Preclinical Evidence That 3'-Deoxy-3'-[18F]Fluorothymidine PET Can Visualize Recovery of Hematopoiesis after Gemcitabine Chemotherapy.

Schelhaas S, Held A, Bäumer N, Viel T, Hermann S, Müller-Tidow C, Jacobs AH.

Cancer Res. 2016 Dec 15;76(24):7089-7095. Epub 2016 Oct 20.

45.

Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus.

Cusan M, Vegi NM, Mulaw MA, Bamezai S, Kaiser LM, Deshpande AJ, Greif PA, Quintanilla-Fend L, Göllner S, Müller-Tidow C, Humphries KR, Armstrong SA, Hiddemann W, Feuring-Buske M, Buske C.

Blood. 2017 Jan 19;129(3):319-323. doi: 10.1182/blood-2016-04-706978. Epub 2016 Nov 8.

46.

Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾60 years).

Pohlen M, Groth C, Sauer T, Görlich D, Mesters R, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Berdel WE, Stelljes M.

Bone Marrow Transplant. 2016 Nov;51(11):1441-1448. doi: 10.1038/bmt.2016.156. Epub 2016 Jun 13.

PMID:
27295269
47.

Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells.

Uttarkar S, Piontek T, Dukare S, Schomburg C, Schlenke P, Berdel WE, Müller-Tidow C, Schmidt TJ, Klempnauer KH.

Mol Cancer Ther. 2016 Dec;15(12):2905-2915. Epub 2016 Oct 5.

48.

Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.

Stucke-Ring J, Ronnacker J, Brand C, Höltke C, Schliemann C, Kessler T, Schmidt LH, Harrach S, Mantke V, Hintelmann H, Hartmann W, Wardelmann E, Lenz G, Wünsch B, Müller-Tidow C, Mesters RM, Schwöppe C, Berdel WE.

Oncotarget. 2016 Dec 13;7(50):82458-82472. doi: 10.18632/oncotarget.12559.

49.

Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia.

Wass M, Hitz F, Schaffrath J, Müller-Tidow C, Müller LP.

PLoS One. 2016 Oct 12;11(10):e0164587. doi: 10.1371/journal.pone.0164587. eCollection 2016.

50.

A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.

Schliemann C, Gerss J, Wiebe S, Mikesch JH, Knoblauch N, Sauer T, Angenendt L, Kewitz T, Urban M, Butterfass-Bahloul T, Edemir S, Vehring K, Müller-Tidow C, Berdel WE, Krug U.

PLoS One. 2016 Oct 7;11(10):e0164499. doi: 10.1371/journal.pone.0164499. eCollection 2016.

Supplemental Content

Loading ...
Support Center